Gadobutrol

CHEMBL2218860 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
604.7 g/mol
LogP
Phase
4

This gadolinium-based MRI contrast agent has a high concentration formulation that enhances the visibility of tumors and other abnormalities in the brain, spine, and blood vessels. Its high relaxivity and stability make it suitable for a wide range of diagnostic imaging applications.

น้ำหนักโมเลกุล

604.7000 g/mol

TPSA

194.00 Ų

ด้านการรักษา

กลไกการออกฤทธิ์

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C1CN(CCN(CCN(CCN1CC(=O)[O-])CC(=O)[O-])[C@H](CO)[C@@H](CO)O)CC(=O)[O-].[Gd+3]

InChI

InChI=1S/C18H34N4O9.Gd/c23-12-14(15(25)13-24)22-7-5-20(10-17(28)29)3-1-19(9-16(26)27)2-4-21(6-8-22)11-18(30)31;/h14-15,23-25H,1-13H2,(H,26,27)(H,28,29)(H,30,31);/q;+3/p-3/t14-,15-;/m1./s1

Molecular Formula

C18H31GdN4O9

HBD / HBA

3 / 13

พันธะที่หมุนได้

7

อะตอมหนัก

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

This gadolinium-based MRI contrast agent has a high concentration formulation that enhances the visibility of tumors and other abnormalities in the brain, spine, and blood vessels. Its high relaxivity and stability make it suitable for a wide range of diagnostic imaging applications.

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Yes, Gadobutrol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2218860. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6102852. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.